ReviewBioMed research international2018
Hepatitis E: Update on Prevention and Control.
Review in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- A systematic review of the epidemiology of Hepatitis E virus infection in South - Eastern Asia.Virulence · 2021Pooled it
- The global epidemiology of hepatitis E virus infection: A systematic review and meta-analysis.Liver international : official journal of the International Association for the Study of the Liver · 2020Pooled it
- Seroprevalence of hepatitis E virus infection in pregnant women: a systematic review and meta-analysis.Annals of Saudi medicinePooled it
- Hepatitis E and Potential Public Health Implications from a One-Health Perspective: Special Focus on the European Wild Boar (Pathogens (Basel, Switzerland) · 2024Review
- Seroprevalence of the Hepatitis E Virus in Indigenous and Non-Indigenous Communities from the Brazilian Amazon Basin.Microorganisms · 2024Article
- Serological survey on Hepatitis E virus in Namibian dogs, cats, horses, and donkeys.Frontiers in veterinary science · 2024Article
- Prevalence and Risk Factors for Hepatitis E Virus in Wild Boar and Red Deer in Portugal.Microorganisms · 2023Article
- Review
- Hepatitis E Virus Protease Inhibits the Activity of Eukaryotic Initiation Factor 2-Alpha Kinase 4 and Promotes Virus Survival.Journal of virology · 2023Article
- Hepatitis E virus detection in hunted wild boar (Italian journal of food safety · 2022Article
- Viral hepatitis: A global burden needs future directions for the management.World journal of gastroenterology · 2022Article
- Hepatitis A and E among immigrants and refugees in Central Brazil.Revista de saude publica · 2022Article
- Detection and Prevention of Virus Infection.Advances in experimental medicine and biology · 2022Article
- Hepatitis E: Genotypes, strategies to prevent and manage, and the existing knowledge gaps.JGH open : an open access journal of gastroenterology and hepatology · 2021Review
- Feasibility of controlling hepatitis E in Jiangsu Province, China: a modelling study.Infectious diseases of poverty · 2021Article
- Hepatitis E Virus in People Who Use Crack-Cocaine: A Cross-Sectional Study in a Remote Region of Northern Brazil.Viruses · 2021Article
- Epidemiology, diagnosis, vaccines, and bibliometric analysis of the 100 top-cited studies on Hepatitis E virus.Human vaccines & immunotherapeutics · 2021Article
- Fatal Outcome in a Hepatitis E Virus/Human Immunodeficiency Virus Co-Infected Malnourished Child in the Central African Republic.Infectious disease reports · 2020Article
- Hepatitis E Virus ORF2 Inhibits RIG-I Mediated Interferon Response.Frontiers in microbiology · 2020Article
- Acute Hepatitis E in a Young Male.Cureus · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis E virus (HEV) is a common etiology of acute viral hepatitis worldwide. Recombinant HEV vaccines have been developed, but only one is commercially available and licensed in China since 2011. Epidemiological studies have identified genotype 3 as the major cause of chronic infection in immunocompromised individuals. Ribavirin has been shown to be effective as a monotherapy to induce HEV clearance in chronic patients who have undergone solid organ transplant (SOT) under immunosuppressive therapy. Efforts and improvements in prevention and control have been made to reduce the instances of acute and chronic hepatitis E in endemic and nonendemic countries. However, this review shows that further studies are required to demonstrate the importance of preventive vaccination and treatment worldwide, with emphasis on hepatitis E infection in the public health system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.